SINGULAIR's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8007830 | ORGANON | Granule formation |
Oct, 2022
(10 months ago) | |
Singulair is owned by Organon.
Singulair contains Montelukast Sodium.
Singulair has a total of 1 drug patent out of which 1 drug patent has expired.
Expired drug patents of Singulair are:
- US8007830
Singulair was authorised for market use on 26 July, 2002.
Singulair is available in granule;oral dosage forms.
The generics of Singulair are possible to be released after 24 October, 2022.
Drugs and Companies using MONTELUKAST SODIUM ingredient
Market Authorisation Date: 26 July, 2002
Treatment: NA
Dosage: GRANULE;ORAL
How can I launch a generic of SINGULAIR before it's drug patent expiration?
More Information on Dosage
SINGULAIR family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic